BlackRock Inc. Purchases Shares of 3,502,841 Maze Therapeutics, Inc. $MAZE

Key Points

• BlackRock acquired 3,502,841 shares of Maze Therapeutics during the second quarter, valued at approximately $104.5 million and representing about 6.33% of the company.
• Maze shares opened at $27.44, well below their 12-month high of $53.65. The company reported a quarterly loss of $0.76 per share, in line with estimates, and analysts expect a full-year loss of $2.72 per share.
• Analyst sentiment remains broadly positive, with an average “Buy” rating and a $66 consensus price target, although some firms maintain “Sell” ratings. Insiders sold approximately 108,110 shares worth $3.06 million during the last quarter.

BlackRock Inc. purchased a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 3,502,841 shares of the company's stock, valued at approximately $104,525,000. BlackRock Inc. owned approximately 6.33% of Maze Therapeutics as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Maze Therapeutics in the first quarter worth about $57,000. Goldman Sachs Group Inc. bought a new position in Maze Therapeutics during the first quarter valued at approximately $145,000. Rhumbline Advisers purchased a new position in Maze Therapeutics during the 1st quarter valued at approximately $80,000. Geode Capital Management LLC grew its holdings in Maze Therapeutics by 8.8% during the 2nd quarter. Geode Capital Management LLC now owns 231,237 shares of the company's stock valued at $2,838,000 after buying an additional 18,773 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in Maze Therapeutics by 387.0% in the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company's stock worth $52,000 after acquiring an additional 3,371 shares during the last quarter.

Maze Therapeutics Stock Performance

Shares of NASDAQ:MAZE opened at $27.44 on Friday. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. Maze Therapeutics, Inc. has a 12 month low of $13.89 and a 12 month high of $53.65. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -10.89 and a beta of 2.21. The firm's 50-day moving average is $28.74 and its 200 day moving average is $31.90.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). Research analysts predict that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Insider Activity

In other news, CEO Jason V. Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the completion of the sale, the chief executive officer owned 23,337 shares of the company's stock, valued at approximately $699,643.26. The trade was a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the firm's stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total value of $205,050.00. Following the transaction, the insider owned 26,250 shares in the company, valued at $717,675. The trade was a 22.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 108,110 shares of company stock valued at $3,057,531. Corporate insiders own 5.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on MAZE. Weiss Ratings reiterated a "sell (d-)" rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen lowered shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. TD Cowen raised shares of Maze Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. Finally, BTIG Research restated a "buy" rating and issued a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday, August 12th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $66.00.

Maze Therapeutics Profile

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.